Ƶ

Positive KarXT Blood Pressure Data; ADHD Manufacturing Cover-Up? 'Profound Autism'

— News and commentary from the psychiatry world

Ƶ MedicalToday
Illustration of a brain shaped maze.

Karuna Therapeutics released reassuring phase Ib data with its investigational psychiatric drug KarXT; the novel agent is under review with the FDA for an indication in schizophrenia.

A for illegally prescribing combinations of benzodiazepines and stimulants, the Department of Justice said.

, alleging that the company covered up manufacturing problems with its drug methylphenidate (Quillivant XR) for attention deficit-hyperactivity disorder (ADHD). (Fierce Pharma)

A security guard was killed during a ; no patients were harmed and the suspect was killed, according to authorities. (CNN)

One was so crowded, patients were sleeping in conference rooms. (Honolulu Civil Beat)

Amid the growing neurodiversity movement, a rift has developed over the term "." (Washington Post)

More was linked with a significantly lower risk for postpartum depression symptoms. (Obstetrics and Gynecology)

Two former dancers in the Richmond Ballet sued the Virginia company for $21 million in damages for allegedly . (Axios)

For pregnant and postpartum women between the ages of 35 to 44, the more than tripled from 2018 to 2021. (JAMA Psychiatry)

The issued an updated edition of its recommendations for treating mental, neurological, and substance use disorders.

Recent research have renewed interest in the potential use of vaccines to treat the disease. (Reuters)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.